CEO Nils Brünner comments: “In contrast to the majority of solid cancer diseases, malignant melanoma appears to be stimulated by Wnt5a. Therefore, our founder, Professor Tommy Andersson, Lund University, developed a Wnt5a antagonist which we hope will be useful in the treatment of patients with malignant melanoma, a cancer disease with an increasing incidence and an often fatal outcome. We are very pleased that yet another large country has decided to allow our Box-5 patent as it provides WntResearch the needed freedom to operate with Box-5” For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708 About Box-5 Box-5 is an anti-metastatic drug candidate in pre-clinical development. Box-5 as well as Foxy-5 represents new concepts (first-in-class) in the treatment of cancer. Both drug candidates are directed to interfere with the metastatic process. The spread of the tumor is the most common reason of death for cancer patients- Box-5 offers potential shift in the anticancer treatment paradigm in the treatment of some cancer indications including malignant melanoma and gastric cancer. About WntResearch WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients with metastasis. The company’s lead product Foxy-5 is in phase 1 and Box-5 is in pre-clinical phase. The company is focusing on Foxy-5.